Edinburgh Cancer Research UK Centre MRC Institute of Genetics and Molecular Medicine

www.igmm.ac.uk

Neil Carragher (n.carragher@ed.ac.uk)

Edinburgh Cancer Discovery Unit (ECDU) (Est.2011)

Edinburgh Phenotypic Assay Centre (E-PAC) (Est.2015)

University of Edinburgh

Returning to academia after a

career in big pharma

Topics

1. My Career Path: (Industry to Academia to Industry to Academia)

1. Working Industry Vs Academia (personal view!)

2. Life in Industry: Examples of Day-to-day responsibility

3. Life in Academia: Examples of Day-to-day responsibility

4. A changing world in Industry and Academia

o Academic-Industry partnerships

o Academic-Academic partnerships

1. New initiatives in academic training (University of Edinburgh)

1. Tips ? & questions?

Career Path:

Oxford (1993 -1996)

University of Washington, Seattle (1996-1999)

(Dept of Pathology: Atherosclerosis)

Beatson Institute for Cancer Research (1999-2004)

Advanced Science & Technology Lab (2004-2010)

Edinburgh Cancer Research Centre UoE (2010 - ?)

University of Aberdeen: cell & immunobiology (1992)

Glengordon Knitwear Factory, Aberdeen (pom-poms) (1992-1993)

Academia

Industry +PhD

Academia

Academia

Academia

Industry

Industry Academia

Milestones

Timeline

Career development

Reward (bonus/promotion)

Management

Salary

Meetings

Milestones!

Timeline!

Career development

Reward?

Management

Teaching

Salary

Freedom

Continuity (staff & funding)

Meetings!

Publications!

Industry vs Academia Key words:

Associate Principal Scientist:

AstraZeneca BAND D

1.Phenotypic Profiling: 5FTE, 1 contract, 1MSc (+4 collaborators Boston)

(+external collaborators)

2. Functional Profiling: 2FTE

(migration/invasion/angiogenesis)

3. In Vivo/Ex Vivo Imaging: 1FTE +external collaborators(1postdoc/1PhD)

(migration/invasion/angiogenesis)

-Project management (Planning/Reporting)

-Scoping, initiating and managing collaborations

-Technology Evaluation (visits, alliances with vendors/academics)

-Line Management

-PR

-Lab work

Project Management:

Day to day

Line Management: 5 FTE (matrix management)

1.Phenotypic Profiling: 4FTE, 1 contract, 1MSc (+4 collaborators Boston)

(+external collaborators MIT)2. Functional Profiling: 2FTE

(migration/invasion/angiogenesis)

3. Drug combinations strategy: across all disease areas and all AstraZeneca sites.

Manage core matrix team of 16 FTE & 3 external collaborations (multi-million dollar budget!)

4. Cancer strategy matrix team:

-Project management (Planning/Reporting)

-Scoping, initiating and managing collaborations

-Strategy, Continuous Improvement: productivity/performance/innovation

-Technology Evaluation (visits, alliances with vendors/academics)

-Line Management

-PR

-Lots of travel and Lab work no more!

Project Management:

Day to day

Line Management: 5 FTE

Principal Scientist:

AstraZeneca BAND E

Principal Investigator

University of Edinburgh

1. 4 major industry collaboration

2. ERC phenotypic screening projects

3. Co-applicant and supervisor in large brain cancer program

4. Co-applicant and supervisor in pro-drug/chemical biology program

-Project management (Planning/Reporting)

-Scoping, initiating and managing collaborations

-Technology Evaluation (visits, alliances with vendors/academics)

-Line Management

-PR (More publications and conference talks)

-Occasional teaching, essay marking.

-PhD studentship (second supervisor), Lab placements; Mentoring

Project Management:

Day to day

Line Management: 7 FTE (3 post doc; 3 Research assistants; 1 PhD studenship)

Start from bottom up: Laboratory space and £25,000

Professor of Drug Discovery

University of Edinburgh

Principal Investigator responsibilities + New responsibilities:

• Head of Institute Biological Safety Committee

• Head of Institute Translation & Commercialization

• CSO Phenomics Discovery Initiative

• Director of the Edinburgh Cancer Discovery Unit

• Director of the Edinburgh Phenotypic Assay Centre

• School of Biological Sciences Research Committee

• College of Medicine/Vet Medicine Innovation Committee

Cancer Research UK:

• Small molecule expert review panel

• New Agents Committee

• Advisory panel for CRUK Centre for Drug Development

ECDU: Western

General

College of Science &

Engineering

E-PAC: Royal infirmary

… an opportunity for cross-disciplinary research

integrated approach

• basic biologists• geneticists• translational scientists• chemists• chemical biologists• physicists• engineers• computational biologists• mathematicians• pharmacologists• clinician scientists• phase 1 and phase 11

doctors• surgeons• pathologists• NHS consultants

‘smarter’ clinical trials

Interface between:Basic Research, Clinical research,

Health Service & Industry

better treatments

“ comprehensive translational centre” model of research and service

“filling the skills gap”

Acknowledgements

Academic - Industry - Partnerships

Poster1015–findoutaboutjoiningPDI

Academia PharmaIndustry

• Accesstoworld-classfacili es• Bestinclasscompoundlibrary• Needsdefinedbyindustry• Humandiseaserelevantassays• Assayssourcedfromacademia&clinic• Riskandcostsharingmodel• Wetdiligence• Accesstoprecompe vedata• Sharedconsor umdata&knowledge• Nego atedcontractandannualfee

Public–PrivatePartnershiptodevelopinnova ve,validated,

phenotypicassays

Foundingindustrialpartner

Poster1015–findoutaboutjoiningPDIhttp://npsc.ac.uk/pdi

http://www.ed.ac.uk/medicine-vet-

medicine/research/edinburgh-scientific-academic-track

http://www.ed.ac.uk/institute-academic-development

Proposed: Industry Academic Fellowship Scheme

“Innovation” and “up-to-date”Embrace new approaches/technologies

Broad skill set (adaptability)

&

Hard work = Motivated

Tips:

Competitive CV:Relevant skills, Relevant work experience, Publications, References

Plan your training and your career path for your dream job:

-Look at Job description of current advertised posts-if you do not

have the skills required then seek training course/work experience

Science more fun than making pom-poms!

ECDU/EPAC: Uni. of Edinburgh: Chemistry

John Dawson Margaret Frame, David Gray Asier Unciti-Broceta

Kenny Macleod Val Brunton Craig Fraser

Dahlia Doughty-Shenton Alan Serrels Jason Weiss

Ashraff Makda Bryan Serrels

Alison Munro Steve Pollard, Paul Brennan

Nils Lindstrom Dario Magnani

Ida Niklasson Siddharthan Chandran

Scott Warchal Duncan Sproul

Hitesh Patel Guido Sanguinetti

NPSC: Andrew Hopkins; Paul Andrews; Daniel Ebner; Denise Barrault

AcknowledgementsAcknowledgements

Centre for Drug Development

Carrick

Therapeutics, Ltd.

Paul Timpson